Cargando…

Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

BACKGROUND: Older individuals often have a reduced immune response to influenza vaccination, which might be improved by administering a higher vaccine dose. We compared the immune response to two single doses of the AS03(A)-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillard, Paul, Giet, Didier, Heijmans, Stéphane, Dramé, Mamadou, Walravens, Karl, Roman, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233031/ https://www.ncbi.nlm.nih.gov/pubmed/25354581 http://dx.doi.org/10.1186/1745-6215-15-419

Ejemplares similares

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
por: Heijmans, Stéphane, et al.
Publicado: (2011)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

Long-term booster schedules with AS03(A)-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
por: Gillard, Paul, et al.
Publicado: (2014)

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies
por: Garcia-Sicilia, José, et al.
Publicado: (2015)

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
por: Nagai, Hideaki, et al.
Publicado: (2010)

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
por: van der Most, Robbert G., et al.
Publicado: (2017)

Modulation of Adjuvant Arthritis by Cellular and Humoral Immunity to Hsp65
por: Kim, Eugene Y., et al.
Publicado: (2016)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

Yoga as an Adjuvant therapy in management of migraine- An open label randomised trial
por: Kumari, Sweety, et al.
Publicado: (2022)

Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
por: Herrera, Ma Teresa, et al.
Publicado: (2013)

Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant
por: Cao, Yan, et al.
Publicado: (2018)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

ICAMs are dispensable for influenza clearance and anti-viral humoral and cellular immunity
por: Kozlovski, Stav, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014)

Non‐neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system
por: Friel, Damien, et al.
Publicado: (2020)

Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice
por: Song, Li, et al.
Publicado: (2016)

Simultaneous enhancement of cellular and humoral immunity by the high salt formulation of Al(OH)(3) adjuvant
por: Luo, Min, et al.
Publicado: (2017)

Simple nanoliposomes encapsulating Lycium barbarum polysaccharides as adjuvants improve humoral and cellular immunity in mice
por: Bo, Ruonan, et al.
Publicado: (2017)

Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins
por: Akache, Bassel, et al.
Publicado: (2019)

Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses
por: Prior, J. Timothy, et al.
Publicado: (2021)

Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus
por: Chang, Chi-Chieh, et al.
Publicado: (2023)

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue
por: Prinsen, Hetty, et al.
Publicado: (2015)

Adjuvant testosterone therapy in chronic heart failure (ATTIC): a randomised open-label trial
por: Dhar, Minakshi, et al.
Publicado: (2022)

Intranasal Delivery of Influenza rNP Adjuvanted with c-di-AMP Induces Strong Humoral and Cellular Immune Responses and Provides Protection against Virus Challenge
por: Sanchez, Maria Victoria, et al.
Publicado: (2014)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity
por: Pattacini, Laura, et al.
Publicado: (2012)

Combined Exercise Training and l-Glutamine Supplementation Enhances Both Humoral and Cellular Immune Responses after Influenza Virus Vaccination in Elderly Subjects
por: Monteiro, Fernanda R., et al.
Publicado: (2020)

Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice
por: Barroso, Shana P. C., et al.
Publicado: (2015)

Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome
por: Prinsen, Hetty, et al.
Publicado: (2012)

Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity
por: Rosendahl Huber, Sietske K., et al.
Publicado: (2019)

A polyvalent virosomal influenza vaccine induces broad cellular and humoral immunity in pigs
por: Haach, Vanessa, et al.
Publicado: (2023)

Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy
por: Mannino, Salvatore, et al.
Publicado: (2012)

AS03(B)-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial
por: Kosalaraksa, Pope, et al.
Publicado: (2015)

Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant, rOv-ASP-1
por: Jiang, Jiu, et al.
Publicado: (2016)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study
por: Beigel, John H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vvs6u1m5s2ibu4aer6gmrnv0s9